In contrast, 10 nM of trametinib was insufficient to block pERK signaling in the other non-RAS/RAF mutant NB, while neither SHP2 inhibitors reduced pERK in the RAS mt NB cells, but it did reduce pERK in the RAS/RAF WT NB cells, consistent with the central importance of pERK suppression for MAPK pathway inhibitors (Figure S5A). Here, PTPN11 is linked to neuroblastoma.